FIDIC Kırmızı Kitap Kapsamında İnşaat Sözleşmelerinde Süre Uzatımı

Çevremizde sıkça gördüğümüz, günlük hayatımızın bir parçası olan ve ekonomik olarak da büyük değer ifade eden inşaatlar için akdedilen inşaat sözleşmelerinde tamamlanma süresi sözleşmenin önemli bir unsurudur. Bu önemine istinaden taraflarca akdedilen inşaat sözleşmelerinde tamamlanma süresinin, hangi hallerde süre uzatımı ve buna ilave olarak ek ödeme istenebileceğinin ve gecikme halinde meydana gelen zarardan sorumluluğun düzenlendiği görülmektedir. İnşaatlar çoğunlukla pek çok farklı şirketin yer aldığı kapsamlı projeler olduklarından süre de dâhil olmak üzere proje esnasında ortaya çıkması muhtemel sorunların çözümü için sözleşmede hükümler öngörülmektedir. Bu kapsamda inşaat sözleşmelerinde sıkça FIDIC’in belirlediği standart kurallar benimsenmektedir. Çalışmamızın kapsamını inşaat işlerindeki sözleşme koşullarını ayrıntılı olarak düzenleyen ve güncellenmiş halinin 2017 yılında yayınlandığı Kırmızı Kitap oluşturmaktadır. 2017 tarihli Kırmızı Kitap kapsamında çalışmamız yüklenicinin inşaat sözleşmesi uyarınca edimini yerine getirmesi gereken süre kavramı ile kararlaştırılan süre içerisinde tamamlanmayan edimler bakımından yüklenici ve iş sahibinin hak ve talepleri inceleyecektir. Son olarak, inşaat sözleşmelerinde süre uzatımı Türk Borçlar Kanunu çerçevesinde ele alınacaktır

The longitudinal evolution of post-COVID-19 outcomes among hemodialysis patients in Turkey

Introduction: Hemodialysis (HD) patients have increased risk for short-term adverse outcomes of COVID-19. However, complications and survival at the post-COVID-19 period have not been published extensively.Methods: We conducted a national, multicenter observational study that included adult maintenance HD patients recovered from confirmed COVID-19. A control HD group without COVID-19 was selected from patients in the same center. We investigated the characteristics and outcomes in the follow-up of HD patients and compare them with the non-COVID-19 group.Results: A total of 1223 patients (635 patients in COVID-19 group, 588 patients in non-COVID-19 group) from 47 centers were included in the study. The patients' baseline and HD characteristics were almost similar. The 28th-day mortality and mortality between 28th day and 90th day were higher in the COVID-19 group than non-COVID-19 group (19 [3.0%] patients vs. none [0%]; 15 [2.4%] patients vs. 4 [0.7%] patients, respectively). The presence of respiratory symptoms, rehospitalization, need for home oxygen therapy, lower respiratory tract infection, and arteriovenous (AV) fistula thrombosis was significantly higher in the COVID-19 group in both the first 28 days and between 28 and 90 days. In the multivariable analysis, age (odds ratio [OR] [95% CI]: 1.029 [1.004-1.056]), group (COVID-19 group vs. non-COVID-19 group) (OR [95% CI]: 7.258 [2.538-20.751]), and vascular access type (tunneled catheter/AV fistula) (OR [95% CI]: 2.512 [1.249-5.051]) were found as independent parameters related to 90-day mortality.Conclusion: In the post-COVID-19 period, maintenance HD patients who have had COVID-19 have increased rehospitalization, respiratory problems, vascular access problems, and high mortality compared with the non-COVID-19 HD patients

The longitudinal evolution of post–COVID-19 outcomes among hemodialysis patients: A nationwide multicentre controlled study

BACKGROUND AND AIMS: Haemodialysis (HD) patients are at increased risk for adverse short-term consequences of COVID-19. In this study, we investigated the characteristics of chronic HD patients in the post-COVID-19 period and compared them with the control group. METHOD: We conducted a national multicentre observational study involving adult chronic HD patients recovering from COVID-19. The control HD group was selected from patients with similar characteristics who did not have COVID-19 in the same center. SARS-CoV-2 RT-PCR negative patients and patients in the active period of COVID-19 were not included. RESULTS: A total of 1223 patients (635 COVID-19 groups, 588 control groups) were included in the study from the data collected from 47 centres between 21 April 2021 and 11 June 2021. The patients' baseline demographics, comorbidities, medications, HD characteristics and basic laboratory tests were quite similar between the groups (Table 1). 28th-day mortality and between 28th day and 90th day mortality were higher in the COVID-19 group than in the control group [19 (3.0%) patients and 0 (0%) patients;15 (2.4%) patients and 4 (0.7%) patients, respectively]. Presence of respiratory symptoms, rehospitalization, need for home oxygen therapy, lower respiratory tract infection and A-V fistula thrombosis were significantly higher in the COVID-19 group in the first 28 days of illness and between 28 and 90 days. Mortality was significantly associated with preexisting COVID-19, age, current smoking, use of tunneled HD catheter, persistence of respiratory symptoms, rehospitalization, need for home oxygen support, presence of lower respiratory tract infection within 28 days and persistence of respiratory symptoms. CONCLUSION: In the post-COVID-19 period, mortality, rehospitalization, respiratory problems and vascular access problems are higher in maintenance HD patients who have had COVID-19 compared to control HD patients. (Table Presented)